Related Experiment Videos
[Immunological effectiveness of a dried group-A meningococcal polysaccharide vaccine]
Insights
This study evaluated a group A meningococcal polysaccharide vaccine in children aged 5-14. The vaccine demonstrated high immunogenicity, inducing protective IgM antibody levels in 90% of younger children seven months post-immunization.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Meningococcal disease remains a significant public health concern, particularly in certain age groups.
- Effective vaccines are crucial for preventing meningococcal outbreaks.
- Group A meningococcal polysaccharide vaccine development is ongoing.
Purpose of the Study:
- To assess the immunological effectiveness of a dried group A meningococcal polysaccharide vaccine.
- To determine optimal vaccine dosages for different pediatric age groups.
- To evaluate the persistence of the immune response following vaccination.
Main Methods:
- A single-dose immunization study was conducted on children aged 5-14 years.
- Agglutinating antibody levels to group A meningococcal polysaccharide were measured.
- Antibody titers were assessed at 3-4 weeks and 7 months post-immunization.
Main Results:
- The vaccine was found to be highly immunogenic across the studied age range.
- Optimal doses were identified: 25 mcg (5-8 yrs), 50 mcg (9-13 yrs), and 75 mcg (14+ yrs).
- IgM antibodies, indicative of an immune response, were detected in 90% of younger children at a titer of 1:40 or higher, persisting for 7 months.
Conclusions:
- The Gabrichevsky Research Institute's group A meningococcal polysaccharide vaccine is effective in children aged 5-14.
- The vaccine induces a robust and durable IgM antibody response.
- This vaccine represents a promising tool for meningococcal disease prevention in pediatric populations.
Abstract:
The immunological effectiveness of dried group A meningococcal polysaccharide vaccine, developed at the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, for children aged 5-14 years was studied. The intensiveness of the immune response of children to 0.5 ml of the vaccine introduced in a single injection was evaluated by a rise in the level of agglutinating antibodies to group A meningococcal polysaccharide in the sera of the vaccinees 3-4 weeks after immunization with the following optimum doses: 25 micrograms for children aged 5-8 years, 50 micrograms for children aged 9-13 years and 75 micrograms for children aged 14 years and over. The vaccine was shown to be highly immunogenic. Antibodies to group A meningococcal polysaccharide were identified as IgM. These antibodies in a titer of 1:40 and higher could be detected in 90% of the vaccinated children in the younger age group, 7 months after immunization.